学习经历
2010-09 至 2015-01, 中国科学院上海巴斯德研究所，博士
主要工作经历与任职情况
2015-08 至 2019-12, 美国洛克菲勒大学，博士后
2020-01 至 2021-11, 美国哥伦比亚大学，副研究员
2021-12 至 2024-04, 美国哥伦比亚大学，助理教授
2024-05 至 至今, 武汉大学生科院和泰康生命医学中心，双聘教授
主要科研奖励和个人荣誉
2022年获国家自然科学基金高层次人才青年项目支持
2022年获湖北省百人计划
主要研究领域及兴趣
刘立鸿博士团队长期从事针对病毒感染和免疫应答的研究，着重在病原诊断、病毒和宿主相互作用、病毒免疫逃逸、抗体分离与药物筛选、疫苗设计和评估以及基因治疗等方向开展工作。
承担课程
本科生：无
研究生：目前有2名硕士研究生和2名博士研究生
主持课题项目
· 新发突发传染性疾病的抗体分离以及诊断平台建立，国家自然科学基金项目，在研
· Antigenic characterization of emerging SARS-CoV-2 variants and their point mutants in vitro using polyclonal sera from several clinical cohorts and a panel of monoclonal antibodies, NIH-SAVE项目, 在研
发表的论文（*通讯作者）
1. Wang Q, Guo Y, Bowen A, Mellis IA, Valdez R, Gherasim C, Gordon A, Liu L*, Ho DD*. XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1. Cell Host Microbe. 2024 Mar 13;32(3):315-321.e3. (*Corresponding author).
2. Wang Q, Guo Y, Liyuan Liu, Schwanz LT, Li Z, Nair MS, Ho J, Zhang RM, Iketani S, Yu J, Huang Y, Qu Y, Valdez R, Lauring AS, Huang Y, Gordon A, Wang HH, Liu L*, Ho DD*. Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike. Nature. 2023 Dec;624(7992):639-644. (*Corresponding author).
3. Wang Q, Bowen A, Ho J, Zhang RM, Valdez R, Stoneman E, Gordon A, Liu L*, Ho DD*. SARS-CoV-2 neutralising antibodies after a second BA.5 bivalent booster. Lancet. 2023 Nov 18;402(10415):1827-1828. (*Corresponding author).
4. Wang Q, Guo Y, Zhang RM, Ho J, Mohri H, Valdez R, Manthei DM, Gordon A, Liu L*, Ho DD*. Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6. The Lancet Infectious Diseases 2023 Oct;23(10):e397-e398. (*Corresponding author).
5. Wang Q, Guo Y, Tam AR, Valdez R, Gordon A, Liu L*, Ho DD*. Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine. Cell Reports Medicine. 2023 Nov 21;4(11):101258. (*Corresponding author).
6. Liu L*#, Casner RA#, Guo Y#, Wang Q#, Iketani S#, Chan JFW#,Yu J, Dadonaite B, Nair MS, Mohri H, Reddem ER, Yuan S, Poon VK, Chan CC, Yuen KY, Sheng Z, Huang Y, Bloom JD, Shapiro L*, Ho DD*. Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking. Immunity.2023 Oct 10;56(10):2442-2455.e8. (*#First & Corresponding authors).
7. Wang Q, Li Z, Guo Y, Mellis IA, Iketani S, Liu M, Yu J, Valdez R, Lauring AS, Sheng Z, Gordon A, Liu L*, Ho DD*. Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2. iScience. 2023 Oct 18;26(11):108254. (*Corresponding author).
8. Wang Q, Yeh AY, Guo Y, Mohri H, Yu J, Ho DD*, Liu L*. Impaired potency of neutralizing antibodies against cell-cell fusion mediated by SARS-CoV-2. Emerg Microbes Infect. 2023 May 3:2210237. doi: 10.1080/22221751.2023.2210237. Epub ahead of print. (*Corresponding author).
9. Wang Q, Iketani S, Li Z, Liu Liyuan, Guo Y, Huang Y, Bowen AD, Liu M, Wang M, Yu J, Valdez R, Lauring AS, Sheng Z, Wang HH, Gordon A, Liu L*, Ho DD*. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell. 2023 doi.org/10.1016/j.cell.2022.12.018. (*Corresponding author).
10. Wang Q, Bowen A, Tam AR, Valdez R, Stoneman E, Mellis IA, Gordon A, Liu L*, Ho DD. SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster. Lancet Infect Dis. 2023 May;23(5):527-528. (*Corresponding author).
11. Wang Q, Bowen A, Valdez R, Gherasim C, Gordon A, Liu L*, Ho DD*. Antibody Response to Omicron BA.4-BA.5 Bivalent Booster. N Engl J Med. 2023 Feb 9;388(6):567-569. (*Corresponding author).
12. Wang Q, Li Z, Ho J, Guo Y, Yeh AY, Mohri H, Liu M, Wang M, Yu J, Shah JG, Chang JY, Herbas F, Yin MT, Sobieszczyk ME, Sheng Z, Liu L*, Ho DD*. Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation. Lancet Infect Dis. 2022 Oct 31:S1473-3099(22)00694-6. (*Corresponding author).
13. Wang Q, Iketani S, Li Z, Guo Y, Yeh AY, Liu M, Yu J, Sheng Z, Huang Y, Liu L*, Ho DD*. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75. Cell Host Microbe. 2022 Sep 6:S1931-3128(22)00419-X. (*Corresponding author).
14. Wang Q, Guo Y, Iketani S, Nair MS, Li Z, Mohri H, Wang M, Yu J, Bowen AD, Chang JY, Shah JG, Nguyen N, Chen Z, Meyers K, Yin MT, Sobieszczyk ME, Sheng Z, Huang Y, Liu L* & Ho DD*. Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, & BA.5. Nature. 2022 Jul 5:1-3. (*Corresponding author).
15. Liu L#, Iketani S, Guo Y, Reddem ER, Casner RG, Nair MS, Yu J, Chan JF, Wang M, Cerutti G, Li Z, Morano NC, Castagna CD, Corredor L, Chu H, Yuan S, Poon VK, Chan CC, Chen Z, Luo Y, Cunningham M, Chavez A, Yin MT, Perlin DS, Tsuji M, Yuen KY, Kwong PD, Sheng Z, Huang Y, Shapiro L & Ho DD. An antibody class with a common CDRH3 motif broadly neutralizes sarbecoviruses. Science Translational Medicine. 2022; 14(646):eabn6859. (#First author).
16. Iketani S#, Liu L#, Guo Y#, Liyuan Liu#, Chan JF#, Huang Y, Wang M, Luo Y, Yu J, Chu H, Chik KK, Yuen TT, Yin MT, Sobieszczyk ME, Huang Y, Yuen KY, Wang HH, Sheng Z & Ho DD. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature 2022; 604(7906):553-6. (#First author).
17. Liu L#, Iketani S#, Guo Y#, Chan JF#, Wang M#, Liyuan Liu#, Luo Y, Chu H, Huang Y, Nair MS, Yu J, Chik KK, Yuen TT, Yoon C, To KK, Chen H, Yin MT, Sobieszczyk ME, Huang Y, Wang HH, Sheng Z, Yuen KY & Ho DD. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 2022; 602(7898):676-81. (#First author).
18. Cerutti G#, Guo Y#, Liu L#, Liyuan Liu#, Zhang Z, Luo Y, Huang Y, Wang HH, Ho DD, Sheng Z & Shapiro L. Cryo-EM structure of the SARS-CoV-2 Omicron spike. Cell Rep. 2022 Mar 1;38(9):110428. (#First author).
19. Iketani S#, Liu L#, Nair MS#, Chandrashekar A, Mohri H, Wang M, Barouch DH, Huang Y, and Ho DD. Ad26.COV2.S boosts humoral and cellular immune responses following BNT162b2 vaccination. Emerging Microbes & Infections 2021; 10(1):2220-2222. (#First author).
20. Wang P#, Nair MS#, Liu L#, Iketani S#, Luo Y, Guo Y, Wang M, Yu J, Zhang B, Kwong PD, Graham BS, Mascola JR, Chang JY, Yin MT, Sobieszczyk M, Kyratsous CA, Shapiro L, Sheng Z, Huang Y, and Ho DD. Nature 2021; Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7. Nature 2021;593, 130-135. (#First author).
21. Liu L#, Wang P, Nair MS, Yu J, Rapp M, Wang Q, Luo Y, Chan JF, Sahi V, Figueroa A, Guo XV, Cerutti G, Bimela J, Gorman J, Zhou T, Chen Z, Yuen KY, Kwong PD, Sodroski JG, Yin MT, Sheng Z, Huang Y, Shapiro L and Ho DD. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 2020; 584(7821): 450-456. (#First author).
22. Wang P#, Liu L#, Nair MS#, Yin MT#, Luo Y, Wang Q, Yuan T, Mori K, Solis AG, Yamashita M, Purpura LJ, Laracy JC, Yu J, Sodroski J, Huang Y and Ho DD. SARS-CoV-2 Neutralizing Antibody Responses Are More Robust in Patients with Severe Disease. Emerging Microbes & Infections 2020;9(1):2091-2093. (#First author).
23. Wang Q#, Liu L#, Ren W, Gettie A, Wang H, Liang Q, Shi X, Montefiori DC, Zhou T and Zhang L. A Single Substitution in gp41 Modulates the Neutralization Profile of SHIV during In Vivo Adaptation. Cell Rep 2019; 27(9): 2593-2607 (#First author).
24. Liu L#, Wang W, Matz J, Ye C, Bracq L, Delon J, Kimata JT, Chen Z, Benichou S and Zhou P. The Glycosylphosphatidylinositol-Anchored Variable Region of Llama Heavy Chain-Only Antibody JM4 Efficiently Blocks both Cell-Free and T Cell-T Cell Transmission of Human Immunodeficiency Virus Type 1. J Virol 2016; 90(23): 10642-10659. (#First author).
25. Liu L#, Wen M, Zhu Q, Kimata JT and Zhou P. Glycosyl Phosphatidylinositol-Anchored C34 Peptide Derived From Human Immunodeficiency Virus Type 1 Gp41 Is a Potent Entry Inhibitor. J Neuroimmune Pharmacol 2016; 11(3): 601-10. (#First author).
26. Liu L#, Wang W, Yang L, Ren H, Kimata JT and Zhou P. Trimeric glycosylphosphatidylinositol-anchored HCDR3 of broadly neutralizing antibody PG16 is a potent HIV-1 entry inhibitor. J Virol 2013; 87(3): 1899-905. (#First author).
27. Liu L#, Wen M, Wang W, Wang S, Yang L, Liu Y, Qian M, Zhang L, Shao Y, Kimata JT and Zhou P. Potent and broad anti-HIV-1 activity exhibited by a glycosyl-phosphatidylinositol- anchored peptide derived from the CDR H3 of broadly neutralizing antibody PG16. J Virol 2011; 85(17): 8467-76. (#First author).
